{"id":"feprazone","rwe":[{"pmid":"39619532","year":"2024","title":"Retraction of \"Feprazone Prevents Free Fatty Acid (FFA)-Induced Endothelial Inflammation by Mitigating the Activation of the TLR4/MyD88/NF-κB Pathway\".","finding":"","journal":"ACS omega","studyType":"Clinical Study"},{"pmid":"35252733","year":"2022","title":"Correction to \"Feprazone Mitigates IL-1β-Induced Cellular Senescence in Chondrocytes\".","finding":"","journal":"ACS omega","studyType":"Clinical Study"},{"pmid":"33869924","year":"2021","title":"Feprazone Mitigates IL-1β-Induced Cellular Senescence in Chondrocytes.","finding":"","journal":"ACS omega","studyType":"Clinical Study"},{"pmid":"33778274","year":"2021","title":"Feprazone Ameliorates TNF-α-Induced Loss of Aggrecan via Inhibition of the SOX-4/ADAMTS-5 Signaling Pathway.","finding":"","journal":"ACS omega","studyType":"Clinical Study"},{"pmid":"33748580","year":"2021","title":"Feprazone Displays Antiadipogenesis and Antiobesity Capacities in in Vitro 3 T3-L1 Cells and in Vivo Mice.","finding":"","journal":"ACS omega","studyType":"Clinical Study"}],"tags":[{"label":"feprazone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"M01AX18","category":"atc"},{"label":"Active","category":"status"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FEPRAZONE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:07:43.947920+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:07:52.049088+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FEPRAZONE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:07:52.490112+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1452696/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:53.194092+00:00"}},"allNames":"metrazone","offLabel":[],"synonyms":["feprazone","fenilprenazone","methrazone","metrazone","phenylprenazone","pheprazone","prenazone"],"timeline":[],"approvals":[],"brandName":"Metrazone","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"feprazone","explanation":"","oneSentence":"","technicalDetail":"Feprazone exerts its anti-inflammatory and analgesic effects by competitively inhibiting the enzyme cyclooxygenase (COX), which is responsible for the conversion of arachidonic acid to prostaglandins."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1169","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FEPRAZONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FEPRAZONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:16:51.514875","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:07:54.824597+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"nabumetone","drugSlug":"nabumetone","fdaApproval":"1991-12-24","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glucosamine","drugSlug":"glucosamine","fdaApproval":"","relationship":"same-class"},{"drugName":"orgotein","drugSlug":"orgotein","fdaApproval":"","relationship":"same-class"}],"genericName":"feprazone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nabumetone","brandName":"nabumetone","genericName":"nabumetone","approvalYear":"1991","relationship":"same-class"},{"drugId":"glucosamine","brandName":"glucosamine","genericName":"glucosamine","approvalYear":"","relationship":"same-class"},{"drugId":"orgotein","brandName":"orgotein","genericName":"orgotein","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02904837","phase":"NA","title":"Mental Practice Combined With Physical Practice to Improve the Gait Performance of People With Parkinson's Disease","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2015-03","conditions":["Parkinson Disease"],"enrollment":20,"completionDate":"2017-12"},{"nctId":"NCT03565965","phase":"NA","title":"Protocol: Mental Practice Combined With Physical Practice of Gait in Parkinson's Disease.","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2019-01","conditions":["Parkinson Disease"],"enrollment":144,"completionDate":"2019-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000167057","NDDF":"003714","UNII":"7BVX6J0CGR","CHEBI":"CHEBI:31603","INN_ID":"3441","RXNORM":"8673","UMLSCUI":"C0033056","chemblId":"CHEMBL1452696","ChEMBL_ID":"CHEMBL1452696","KEGG_DRUG":"D01305","DRUGBANK_ID":"DB13364","PUBCHEM_CID":"35455","MESH_DESCRIPTOR_UI":"D011298"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":63,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"M01AX18","allCodes":["M01AX18","M01AX68","M02AA16"]},"biosimilarFilings":[],"recentPublications":[{"date":"2024 Nov 26","pmid":"39619532","title":"Retraction of \"Feprazone Prevents Free Fatty Acid (FFA)-Induced Endothelial Inflammation by Mitigating the Activation of the TLR4/MyD88/NF-κB Pathway\".","journal":"ACS omega"},{"date":"2022 Mar 1","pmid":"35252733","title":"Correction to \"Feprazone Mitigates IL-1β-Induced Cellular Senescence in Chondrocytes\".","journal":"ACS omega"},{"date":"2021 Apr 13","pmid":"33869924","title":"Feprazone Mitigates IL-1β-Induced Cellular Senescence in Chondrocytes.","journal":"ACS omega"},{"date":"2021 Mar 23","pmid":"33778274","title":"Feprazone Ameliorates TNF-α-Induced Loss of Aggrecan via Inhibition of the SOX-4/ADAMTS-5 Signaling Pathway.","journal":"ACS omega"},{"date":"2021 Mar 16","pmid":"33748580","title":"Feprazone Displays Antiadipogenesis and Antiobesity Capacities in in Vitro 3 T3-L1 Cells and in Vivo Mice.","journal":"ACS omega"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:07:54.824597+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}